Hospira’s Epoetin Biosimilar Delayed Following CRL Over GMP Violations

Generic Line
A A
Pfizer and its generic injectables arm, Hospira, received a complete response letter for their proposed biosimilar of epoetin alfa, also known as Epogen and Procrit, following manufacturing issues cited in a February FDA warning.

To View This Article:

Login

Subscribe To Generic Line